Deferoxamine (DFO) represents a widely used iron chelator for the treatment of iron overload. Here we describe the use of mitochondrially targeted deferoxamine (mitoDFO) as a novel approach to preferentially target cancer cells. The agent showed marked cytostatic, cytotoxic, and migrastatic properties in vitro, and it significantly suppressed tumor growth and metastasis in vivo. The underlying molecular mechanisms included (i) impairment of iron-sulfur [Fe-S] cluster/heme biogenesis, leading to destabilization and loss of activity of [Fe-S] cluster/heme containing enzymes, (ii) inhibition of mitochondrial respiration leading to mitochondrial reactive oxygen species production, resulting in dysfunctional mitochondria with markedly reduced supercomplexes, and (iii) fragmentation of the mitochondrial network and induction of mitophagy. Mitochondrial targeting of deferoxamine represents a way to deprive cancer cells of biologically active iron, which is incompatible with their proliferation and invasion, without disrupting systemic iron metabolism. Our findings highlight the importance of mitochondrial iron metabolism for cancer cells and demonstrate repurposing deferoxamine into an effective anticancer drug via mitochondrial targeting. SIGNIFICANCE: These findings show that targeting the iron chelator deferoxamine to mitochondria impairs mitochondrial respiration and biogenesis of [Fe-S] clusters/heme in cancer cells, which suppresses proliferation and migration and induces cell death. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/9/2289/F1.large.jpg.

Faculty of Sciences BIOCEV Research Center Charles University Vestec Czech Republic

Institute of Biotechnology of the Czech Academy of Sciences BIOCEV Research Center Vestec Czech Republic

Institute of Molecular Genetics of the Czech Academy of Sciences Prague Czech Republic

School of Medical Science Griffith University Southport Queensland Australia

Zobrazit více v PubMed

Sheftel AD, Mason AB, Ponka P. The long history of iron in the Universe and in health and disease. Biochim Biophys Acta. 2012;1820:161–87.

Paul VD, Lill R. Biogenesis of cytosolic and nuclear iron-sulfur proteins and their role in genome stability. Biochim Biophys Acta. 2015;1853:1528–39.

Gallagher PS, Larkin M, Thillainadesan G, Dhakshnamoorthy J, Balachandran V, Xiao H, et al. Iron homeostasis regulates facultative heterochromatin assembly in adaptive genome control. Nat Struct Mol Biol. 2018;25:372–83.

Huang ML, Lane DJ, Richardson DR. Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid Redox Signal. 2011;15:3003–19.

Ponka P. Cell biology of heme. Am J Med Sci. 1999;318:241–56.

Kubli DA, Gustafsson AB. Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res. 2012;111:1208–21.

Allen GF, Toth R, James J, Ganley IG. Loss of iron triggers PINK1/Parkin-independent mitophagy. EMBO Rep. 2013;14:1127–35.

Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009;1790:702–17.

Rychtarcikova Z, Lettlova S, Tomkova V, Korenkova V, Langerova L, Simonova E, et al. Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. Oncotarget. 2017;8:6376–98.

Lui GY, Kovacevic Z, Richardson V, Merlot AM, Kalinowski DS, Richardson DR. Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget. 2015;6:18748–79.

Chitambar CR. The therapeutic potential of iron-targeting gallium compounds in human disease: From basic research to clinical application. Pharmacol Res. 2017;115:56–64.

Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol. 2013;83:179–90.

Kovar J, Stunz LL, Stewart BC, Kriegerbeckova K, Ashman RF, Kemp JD. Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. Pathobiology. 1997;65:61–8.

Kemp JD, Cardillo T, Stewart BC, Kehrberg E, Weiner G, Hedlund B, et al. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res. 1995;55:3817–24.

Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629–56.

Rohlenova K, Sachaphibulkij K, Stursa J, Bezawork-Geleta A, Blecha J, Endaya B, et al. Selective disruption of respiratory supercomplexes as a new strategy to suppress Her2high breast cancer. Antioxid Redox Signal. 2017;26:84–103.

Truksa J, Dong LF, Rohlena J, Stursa J, Vondrusova M, Goodwin J, et al. Mitochondrially targeted vitamin E succinate modulates expression of mitochondrial DNA transcripts and mitochondrial biogenesis. Antioxid Redox Signal. 2015;22:883–900.

Boukalova S, Stursa J, Werner L, Ezrova Z, Cerny J, Bezawork-Geleta A, et al. Mitochondrial targeting of metformin enhances its activity against pancreatic cancer. Mol Cancer Ther. 2016;15:2875–86.

Sandoval-Acuna C, Fuentes-Retamal S, Guzman-Rivera D, Peredo-Silva L, Madrid-Rojas M, Rebolledo S, et al. Destabilization of mitochondrial functions as a target against breast cancer progression: role of TPP(+)-linked-polyhydroxybenzoates. Toxicol Appl Pharmacol. 2016;309:2–14.

Tong WH, Rouault TA. Functions of mitochondrial ISCU and cytosolic ISCU in mammalian iron-sulfur cluster biogenesis and iron homeostasis. Cell Metab. 2006;3:199–210.

Morrison GR. Fluorometric microdetermination of heme protein. Anal Chem. 1965;37:1124–6.

Pesta D, Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol. 2012;810:25–58.

Vondrusova M, Bezawork-Geleta A, Sachaphibulkij K, Truksa J, Neuzil J. The effect of mitochondrially targeted anticancer agents on mitochondrial (super)complexes. Methods Mol Biol. 2015;1265:195–208.

Yamashita SI, Kanki T. Detection of hypoxia-induced and iron depletion-induced mitophagy in mammalian cells. Methods Mol Biol. 2018;1759:141–9.

Tomkova V, Sandoval-Acuna C, Torrealba N, Truksa J. Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells. Free Radic Biol Med. 2019;143:510–21.

Jobe NP, Zivicova V, Mifkova A, Rosel D, Dvorankova B, Kodet O, et al. Fibroblasts potentiate melanoma cells in vitro invasiveness induced by UV-irradiated keratinocytes. Histochem Cell Biol. 2018;149:503–16.

Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2000.

Torrance JD, Bothwell THCook JD. Tissue iron stores. Methods in hematology. 1980;90–115.

Bayram J, Malcova I, Sinkovec L, Holubova J, Streparola G, Jurnecka D, et al. Cytotoxicity of the effector protein BteA was attenuated in Bordetella pertussis by insertion of an alanine residue. PLoS Pathog. 2020;16:e1008512.

Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 1995;86:4295–306.

Harmer JE, Hiscox MJ, Dinis PC, Fox SJ, Iliopoulos A, Hussey JE, et al. Structures of lipoyl synthase reveal a compact active site for controlling sequential sulfur insertion reactions. Biochem J. 2014;464:123–33.

La P, Yang G, Dennery PA. Mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation stabilizes ISCU protein: implications for iron metabolism. J Biol Chem. 2013;288:12901–9.

Yang C, Matro JC, Huntoon KM, Ye DY, Huynh TT, Fliedner SM, et al. Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB J. 2012;26:4506–16.

Crooks DR, Ghosh MC, Haller RG, Tong WH, Rouault TA. Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. Blood. 2010;115:860–9.

Collins DW, Gudiseva HV, Chavali VRM, Trachtman B, Ramakrishnan M, Merritt WT III, et al. The MT-CO1 V83I polymorphism is a risk factor for primary open-angle glaucoma in African American men. Invest Ophthalmol Vis Sci. 2018;59:1751–9.

Bottani E, Cerutti R, Harbour ME, Ravaglia S, Dogan SA, Giordano C, et al. TTC19 plays a husbandry role on UQCRFS1 turnover in the biogenesis of mitochondrial respiratory complex III. Mol Cell. 2017;67:96–105.

Pryde KR, Taanman JW, Schapira AH. A LON-ClpP proteolytic axis degrades complex I to extinguish ROS production in depolarized mitochondria. Cell Rep. 2016;17:2522–31.

Hentze MW, Kuhn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A. 1996;93:8175–82.

Zhang Q, Du R, Reis Monteiro Dos Santos GR, Yefidoff-Freedman R, Bohm A, Halperin J, et al. New activators of eIF2alpha Kinase Heme-Regulated Inhibitor (HRI) with improved biophysical properties. Eur J Med Chem. 2020;187:111973.

Letts JA, Fiedorczuk K, Sazanov LA. The architecture of respiratory supercomplexes. Nature. 2016;537:644–8.

Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13.

Scheibye-Knudsen M, Fang EF, Croteau DL, Wilson DMBohr VA. Protecting the mitochondrial powerhouse. Trends Cell Biol. 2015;25:158–70.

Thomas RL, Kubli DA, Gustafsson AB. Bnip3-mediated defects in oxidative phosphorylation promote mitophagy. Autophagy. 2011;7:775–7.

Ding WX, Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem. 2012;393:547–64.

Gandalovicova A, Rosel D, Fernandes M, Vesely P, Heneberg P, Cermak V, et al. Migrastatics-anti-metastatic and anti-invasion drugs: promises and challenges. Trends Cancer. 2017;3:391–406.

Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342–55.

Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol. 2002;42:267–81.

Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem. 2003;10:1021–34.

Harima H, Kaino S, Takami T, Shinoda S, Matsumoto T, Fujisawa K, et al. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. BMC Cancer. 2016;16:702.

Alta RYP, Vitorino HA, Goswami D, Teresa Machini M, Esposito BP. Triphenylphosphonium-desferrioxamine as a candidate mitochondrial iron chelator. Biometals. 2017;30:709–18.

Tong WH, Maio N, Zhang DL, Palmieri EM, Ollivierre H, Ghosh MC, et al. TLR-activated repression of Fe-S cluster biogenesis drives a metabolic shift and alters histone and tubulin acetylation. Blood Adv. 2018;2:1146–56.

Maio N, Kim KS, Holmes-Hampton G, Singh A, Rouault TA. Dimeric ferrochelatase bridges ABCB7 and ABCB10 homodimers in an architecturally defined molecular complex required for heme biosynthesis. Haematologica. 2019;104:1756–67.

McCarthy EL, Booker SJ. Destruction and reformation of an iron-sulfur cluster during catalysis by lipoyl synthase. Science. 2017;358:373–7.

Giulivi C, Boveris A, Cadenas E. Hydroxyl radical generation during mitochondrial electron transfer and the formation of 8-hydroxydesoxyguanosine in mitochondrial DNA. Arch Biochem Biophys. 1995;316:909–16.

Ploumi C, Daskalaki I, Tavernarakis N. Mitochondrial biogenesis and clearance: a balancing act. FEBS J. 2017;284:183–95.

Kiryu-Seo S, Tamada H, Kato Y, Yasuda K, Ishihara N, Nomura M, et al. Mitochondrial fission is an acute and adaptive response in injured motor neurons. Sci Rep. 2016;6:28331.

Chourasia AH, Boland ML, Macleod KF. Mitophagy and cancer. Cancer Metab. 2015;3:4.

Seebacher NA, Richardson DR, Jansson PJ. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death Dis. 2016;7:e2510.

Repnik U, Cesen MH, Turk B. The use of lysosomotropic dyes to exclude lysosomal membrane permeabilization. Cold Spring Harb Protoc. 2016;2016.

Dong LF, Jameson VJ, Tilly D, Prochazka L, Rohlena J, Valis K, et al. Mitochondrial targeting of alpha-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy. Free Radic Biol Med. 2011;50:1546–55.

Modica-Napolitano JS, Aprille JR. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev. 2001;49:63–70.

Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them?. Trends Cell Biol. 2008;18:165–73.

Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–58.

Zanotelli MR, Goldblatt ZE, Miller JP, Bordeleau F, Li J, VanderBurgh JA, et al. Regulation of ATP utilization during metastatic cell migration by collagen architecture. Mol Biol Cell. 2018;29:1–9.

Ziegler PK, Bollrath J, Pallangyo CK, Matsutani T, Canli O, De Oliveira T, et al. Mitophagy in intestinal epithelial cells triggers adaptive immunity during tumorigenesis. Cell. 2018;174:88–101.

NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation

Chelation of Mitochondrial Iron as an Antiparasitic Strategy